Dive into the archives.
- What’s the Point of Extavia?
Featured Story Oct. 16, 2009
By Angela Maas, Managing Editor
Another drug in the self-injected multiple sclerosis (MS) class recently came onto the marketplace. But many within the pharmaceutical industry are saying that other than giving Novartis an entry into the MS market before its [...]
- Novartis says FTY720 reduces relapses
ZURICH, Sept 30 (Reuters) – Swiss drugmaker Novartis AG said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.
Initial results from the two-year Phase III study show that oral FTY720 was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing-remitting multiple sclerosis, [...]
- Generic Betaseron Wins FDA Approval
By Eva von Schaper
Aug. 17 (Bloomberg) — Novartis AG won U.S. Food and Drug Administration approval to sell its Extavia multiple sclerosis treatment, its brand of Bayer AG’s Betaseron.
Extavia, a form of interferon beta-1b, can be used in patients with early and relapsing forms of multiple sclerosis, Basel, Switzerland-based Novartis said in a statement today.
Selling [...]
- Merck Sumbits Cladribine Application for EU Approval
July 23, 2009 — 9:05am ET | By John Carroll
Racing to beat Novartis to the world’s biggest drug markets with a new oral therapy for multiple sclerosis, Merck KGaA has filed for regulatory approval of cladribine in Europe and plans to file in the U.S. later this quarter.
The application brings Merck ”closer to the possibility of providing an [...]
- Hot off the AAN Press: Fingolimod effective but safety an issue
UPDATE 3-Novartis MS drug effective but safety an issue
ZURICH, April 29 (Reuters) – Novartis AG said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it reported a new patient death.
Novartis said the patient died from aspiration pneumonia related to a [...]
- Novartis MS drug linked to new side effect
LONDON, April 14 — Fresh side-effect problems have emerged with Novartis AG’s experimental oral multiple sclerosis (MS) drug FTY720, with doctors reporting a case of haemorrhaging focal encephalitis.
A case report on the patient who developed the condition after taking part in a Phase III clinical trial of the medicine — one of the big hopes [...]
- The Age of Orals: Who Will Win the Race to the Market?
Jan 23, 2009
Oral Cladribine Reduces MS Relapses in Phase 3 Clinical Trial
Oral cladribine (EMD Serono) reduced the relapse rate significantly more than inactive placebo in the phase 3 “CLARITY” study of 1,326 people with relapsing-remitting MS. These initial results – the first from any phase 3 study of oral therapy for MS — are reported [...]
